Format

Send to

Choose Destination
Expert Rev Hematol. 2020 Jan 22:1-13. doi: 10.1080/17474086.2020.1711732. [Epub ahead of print]

Targeting epigenetic regulators in the treatment of T-cell lymphoma.

Author information

1
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
2
Faculty of Medicine, Suez Canal University, Ismailia, Egypt.

Abstract

Introduction: T-cell lymphomas represent a broad group of malignant T-cell neoplasms with marked molecular, clinical, and biologic heterogeneity. Survival rates after conventional chemotherapy regimens are poor for most subtypes and new therapies are needed. Rapidly expanding knowledge in the field of epigenomics and the development of an increasing number of epigenetic-modifying agents have created new opportunities for epigenetic therapies for patients with this complex group of diseases.Areas covered: The present review summarizes current knowledge on epigenetic alterations in T-cell lymphomas, availability, and mechanisms of action of epigenetic-modifying agents, results of clinical trials of epigenetic therapies in T-cell lymphomas, status of FDA approval, and biomarker approaches to guide therapy. Promising future directions are discussed.Expert opinion: Mutations in epigenetic-modifying genes are among the most common genetic alterations in T-cell lymphomas, highlighting the potential for epigenetic therapies to improve management of this group of diseases. Single-agent efficacy is well documented, leading to FDA approval for several indications, but overall response rates and durability of responses remain modest. Critical next steps for the field include optimizing combination therapies that incorporate epigenetic-modifying agents and developing predictive biomarkers that help guide patient and drug selection.

KEYWORDS:

DNA methylation; Epigenetics; angioimmunoblastic T-cell lymphoma; histone deacetylase inhibitor; peripheral T-cell lymphoma; predictive biomarkers; targeted therapy

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center